Palvella Therapeutics (PVLA) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Palvella Therapeutics (PVLA) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-46.86% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
34.98% |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Palvella Therapeutics |
1.42 Bn |
1.16 Bn |
- |
-1.33% |
| Date | Value |
|---|
| Mar 31, 2026 |
-1.33% |
| Sep 30, 2025 |
1.65% |
| Jun 30, 2025 |
8.09% |
| Mar 31, 2025 |
-3.14% |
| Dec 31, 2024 |
32.60% |
| Sep 30, 2024 |
28.43% |
| Jun 30, 2024 |
36.13% |
| Mar 31, 2024 |
18.57% |
| Dec 31, 2023 |
45.48% |
| Sep 30, 2023 |
4.55% |
| Jun 30, 2023 |
36.87% |
| Mar 31, 2023 |
-62.42% |
| Sep 30, 2022 |
-66.33% |
| Jun 30, 2022 |
-1.23% |
| Mar 31, 2022 |
10.33% |
| Dec 31, 2021 |
1.97% |
| Sep 30, 2021 |
-45.64% |
| Jun 30, 2021 |
-335.42% |
| Mar 31, 2021 |
16.59% |
| Dec 31, 2020 |
-54.05% |
